Approved studies using CPRD Data

Applications to access CPRD data for observational research are reviewed by the Independent Scientific Advisory Committee (ISAC). Approval by ISAC is required for researchers to carry out their proposed studies.

A summary of all ISAC-approved protocols, including a lay and technical summary of the proposed research, is published three months after researchers have access to the data to begin their study.

The table below includes all ISAC-approved protocols submitted to CPRD from 1st July 2015. Searches can be carried out using applicant names, approval date or by using key words within the protocol title. Protocols below are listed in order of date of approval.

 

ISAC Approval Date Title
31/10/2018 Determine the association between RSV/bronchiolitis episodes in young children and subsequent childhood episodes of wheeze and asthma (up to age 10 years), using a birth cohort
31/10/2018 Patient and practice level factors associated with influenza vaccine uptake among adults in England: a 7-year multi-level retrospective cohort study
30/10/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT):Study 15 - Replication of "Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events."
29/10/2018 Burden of meningococcal disease (MD) in the UK during the period 2008-2017 - retrospective database analysis
25/10/2018 Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study
25/10/2018 Development and validation of a prognostic model for use in primary care which estimates the probability of individuals with non-diabetic hyperglycaemia developing type 2 diabetes
25/10/2018 Burden of Hypereosinophilic syndrome (HES) in the UK
12/10/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 13 - Replication of "Metformin and the incidence of viral associated cancers in patients with type 2 diabetes."
11/10/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT):Study 15 - Replication of "Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events."
11/10/2018 Incretin-based drugs and the risk of lung cancer in patients with type 2 diabetes
03/10/2018 A cross sectional description of prostate cancer subgroups.
28/09/2018 Towards an accessible methodology in precision medicine: methods for time-to-event data and non-regular inferences with an application to treatment of type 2 diabetes
24/09/2018 Identifying patients with familial hypercholesterolemia who could benefit from treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Development and validation of a logistic regression predictive model
21/09/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 7 - Replication of "Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis"
20/09/2018 An investigation of the adverse outcomes and resource use associated with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and their relationship with glucocorticoid (GC) treatment
20/09/2018 The resource use, financial costs and related epidemiology of treating people with HIV and its associated comorbidities vs. matched controls in the UK general population
19/09/2018 Impact of EU label changes for systemic diclofenac & hydroxyzine products: post-referral prescribing trends
11/09/2018 Uptake of pneumococcal and zoster vaccines by clinical risk groups in England
11/09/2018 Difference in Response to Inhaled Corticosteroids between smoking and non-smoking asthma patients.
10/09/2018 Mortality trends in people with and without type 2 diabetes in UK: a CPRD observational study